雷达财经 文|冯秀语 编|李亦辉11月13日,海思科(证券代码:002653)公告,公司近日获得国家药品监督管理局下发的《药物临床试验批准通知书》,批准其自主研发的创新药HSK39297片开展新适应症年龄相关性黄斑变性(AMD)的临床试验。AMD是一种影响中老年人中心视野与视力的常见视网膜黄斑区退行性疾病,在我国患病人数众多且预计未来将大幅增加。当前临床治疗手段存在不足,如抗血管内皮生长因子治疗...
Source Link雷达财经 文|冯秀语 编|李亦辉11月13日,海思科(证券代码:002653)公告,公司近日获得国家药品监督管理局下发的《药物临床试验批准通知书》,批准其自主研发的创新药HSK39297片开展新适应症年龄相关性黄斑变性(AMD)的临床试验。AMD是一种影响中老年人中心视野与视力的常见视网膜黄斑区退行性疾病,在我国患病人数众多且预计未来将大幅增加。当前临床治疗手段存在不足,如抗血管内皮生长因子治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.